Several factors may influence the development of irAEs during treatment with ICIs, including the cancer type, molecular target (CTLA-4 or PD-1/PD-L1), single agent administration or combined checkpoint blockade and/or sequential use of different types of ICIs. The gene discussed is PDCD1; the disease is cancer.